We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mesoblast Limited | ASX:MSB | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.18 | 1.175 | 1.18 | 0.00 | 01:00:00 |
By Chris Wack
Mesoblast Ltd. said it has filed a request and expects to hold a Type C meeting with the U.S. Food & Drug Administration during the current quarter to discuss the pathway to U.S. regulatory approval for rexlemestrocel-L following the recently completed 404 patient Phase 3 trial in patients with chronic inflammatory back pain due to degenerative disc disease.
The company said the move is part of its strategy for bringing rexlemestrocel-L to patients in the U.S. with chronic low back pain due to degenerative disc disease refractory.
Mesoblast said it plans to use the results from a planned U.S. trial to support potential product approvals in both the U.S. and EU by including 20% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. Mesoblast and its partner in Europe and Latin America, Grunenthal, have amended their collaboration agreement, with Mesoblast being eligible to receive payments up to $112.5 million prior to product launch in the EU, inclusive of $17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved.
Cumulative milestone payments could reach $1 billion depending on the final outcome of Phase 3 studies and patient adoption. Mesoblast also will receive tiered double-digit royalties on product sales as per the original agreement.
Mesoblast shares were up 8% to $8.05 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 01, 2021 07:49 ET (11:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Mesoblast Chart |
1 Month Mesoblast Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions